Pancreatic cancer could be treated with a Parkinson's drug
The new research suggests that carbidopa, which is a drug approved by the Food and Drug Administration (FDA) and widely used to treat Parkinson's disease, has significant anti-cancer properties.
Carbidopa is typically used in conjunction with levodopa (L-Dopa) to treat Parkinson's disease. And previous studies have shown that patients with Parkinson's tend to have a lower incidence of cancer.
In older research, scientists investigated whether or not it was the drug L-Dopa that yielded the anti-cancer effect, but they did not find any significant results.
So now, a team led by Dr. Yangzom Bhutia - from the Texas Tech University Health Sciences Center (TTUHSC) in Lubbock - hypothesized that carbidopa alone could have anti-cancer properties.
Commenting on the motivation for the research, Dr. Bhutia says, "Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon."
"Carbidopa is never used by itself as a drug for any disease," she adds. "But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."
The first author of the study is Jiro Ogura, of the Department of Cell Biology and Biochemistry at TTUHSC, and the findings were published in the Biochemical Journal.
Article originally published in Medical News Today, www.medicalnewstoday.com.
To read full article, please visit https://www.medicalnewstoday.com/articles/319578.php.
Related Stories
TTUHSC’s Graduate School of Biomedical Sciences Hosts Student Research Week
The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.
TTUHSC Researcher Receives NIH Grant to Study Vulnerabilities in Specific Cancer Types
The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.
The Hype Around Artificial Intelligence
Richard Greenhill, DHA, FISQua, FACHE, discusses the hype and reality surrounding AI in healthcare.
Recent Stories
TTUHSC Jerry H. Hodge School of Pharmacy Class of 2022 Honored at Commencement Ceremony
The TTUHSC Jerry H. Hodge School of Pharmacy celebrated the Class of 2022 May 21 with its annual commencement ceremony.
Living with Dysphagia
Dysphagia is a swallowing disorder that affects a person’s ability to eat or drink, affecting between 300,000 and 700,000 people in the United States each year.
Equip Yourself with Lifesaving Skills – Know How to Stop the Bleed During National Stop the Bleed Month
Brittany Bankhead, M.D., an assistant professor of surgery for the Division of Trauma, Burns and Critical Care at the Texas Tech University Health Sciences Center, said life-threatening bleeding can happen in everyday scenarios.